MPs: Drug regulators slow on uptake

Shame, shame on Britain's National Health Service. Parliament is calling the agency to task for dragging its feet on reviewing and adopting new drugs. A House of Commons committee also criticizes NHS experts for failing to toss out old treatments that aren't considered effective anymore.

According to the critical MPs, the National Institute for Clinical Excellence--which is charged with decided which drugs and treatments the NHS will pay for--makes decisions not based on empirical evidence and without regard to the NHS budget. The MPs suggested that all drugs be appraised as they're launched, and the the most cost-effective be made available immediately.

The group acknowledged that NICE faces all sorts of challenges to quick work, including scarce resources. The Department of Health, which oversees the NHS and NICE, says it will respond to the report soon.

- read the report in The Telegraph

Related Articles:
Is the NHS really cutting drug spending by 10%?. Report
UK aims to slice drug prices 10%. Report
Europe moves to reclaim center stage. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.